Search Results - "Jukema, J. Wouter"

Effects of fatty acids on T cell function: role in atherosclerosis by Reilly, Nathalie A., Lutgens, Esther, Kuiper, Johan, Heijmans, Bastiaan T., Jukema, J. Wouter

“…T cells are among the most common cell types present in atherosclerotic plaques and are increasingly being recognized as a central mediator in atherosclerosis…”
Get full text

Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome by Schwartz, Gregory G, Steg, P. Gabriel, Szarek, Michael, Bhatt, Deepak L, Bittner, Vera A, Diaz, Rafael, Edelberg, Jay M, Goodman, Shaun G, Hanotin, Corinne, Harrington, Robert A, Jukema, J. Wouter, Lecorps, Guillaume, Mahaffey, Kenneth W, Moryusef, Angèle, Pordy, Robert, Quintero, Kirby, Roe, Matthew T, Sasiela, William J, Tamby, Jean-François, Tricoci, Pierluigi, White, Harvey D, Zeiher, Andreas M

“…Among patients who had had an acute coronary syndrome, the risk of death from coronary heart disease, nonfatal myocardial infarction, stroke, or unstable…”
Get full text

EU-Wide Cross-Sectional Observational Study of Lipid-Modifying Therapy Use in Secondary and Primary Care: the DA VINCI study by Ray, Kausik K, Molemans, Bart, Schoonen, W Marieke, Giovas, Periklis, Bray, Sarah, Kiru, Gaia, Murphy, Jennifer, Banach, Maciej, De Servi, Stefano, Gaita, Dan, Gouni-Berthold, Ioanna, Hovingh, G Kees, Jozwiak, Jacek J, Jukema, J Wouter, Kiss, Robert Gabor, Kownator, Serge, Iversen, Helle K, Maher, Vincent, Masana, Luis, Parkhomenko, Alexander, Peeters, André, Clifford, Piers, Raslova, Katarina, Siostrzonek, Peter, Romeo, Stefano, Tousoulis, Dimitrios, Vlachopoulos, Charalambos, Vrablik, Michal, Catapano, Alberico L, Poulter, Neil R

“…To provide contemporary data on the implementation of European guideline recommendations for lipid-lowering therapies (LLTs) across different settings and…”
Get full text

High-Sensitivity Cardiac Troponin Concentration and Risk of First-Ever Cardiovascular Outcomes in 154,052 Participants by Willeit, Peter, Welsh, Paul, Evans, Jonathan D.W., Tschiderer, Lena, Boachie, Charles, Jukema, J. Wouter, Ford, Ian, Trompet, Stella, Stott, David J., Kearney, Patricia M., Mooijaart, Simon P., Kiechl, Stefan, Di Angelantonio, Emanuele, Sattar, Naveed

“…High-sensitivity assays can quantify cardiac troponins I and T (hs-cTnI, hs-cTnT) in individuals with no clinically manifest myocardial injury. The goal of…”
Get full text

Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes by Cannon, Christopher P, Blazing, Michael A, Giugliano, Robert P, McCagg, Amy, White, Jennifer A, Theroux, Pierre, Darius, Harald, Lewis, Basil S, Ophuis, Ton Oude, Jukema, J. Wouter, De Ferrari, Gaetano M, Ruzyllo, Witold, De Lucca, Paul, Im, KyungAh, Bohula, Erin A, Reist, Craig, Wiviott, Stephen D, Tershakovec, Andrew M, Musliner, Thomas A, Braunwald, Eugene, Califf, Robert M

“…In this trial, patients with an acute coronary syndrome within the previous 10 days were randomly assigned to simvastatin plus either ezetimibe or placebo. At…”
Get full text

The AT04A vaccine against proprotein convertase subtilisin/kexin type 9 reduces total cholesterol, vascular inflammation, and atherosclerosis in APOE3Leiden.CETP mice by Landlinger, Christine, Pouwer, Marianne G, Juno, Claudia, van der Hoorn, José W A, Pieterman, Elsbet J, Jukema, J Wouter, Staffler, Guenther, Princen, Hans M G, Galabova, Gergana

“…Proprotein convertase subtilisin/kexin type 9 (PCSK9) has emerged as a promising therapeutic target for the treatment of hypercholesterolaemia and…”
Get full text

Vein graft failure: from pathophysiology to clinical outcomes by de Vries, Margreet R., Simons, Karin H., Jukema, J. Wouter, Braun, Jerry, Quax, Paul H. A.

“…Key Points Thrombosis, constrictive remodelling, intimal hyperplasia, and unstable atherosclerotic lesions are the critical mechanisms contributing to vein…”
Get full text

Lipid-Reduction Variability and Antidrug-Antibody Formation with Bococizumab by Ridker, Paul M, Tardif, Jean-Claude, Amarenco, Pierre, Duggan, William, Glynn, Robert J, Jukema, J. Wouter, Kastelein, John J.P, Kim, Albert M, Koenig, Wolfgang, Nissen, Steven, Revkin, James, Rose, Lynda M, Santos, Raul D, Schwartz, Pamela F, Shear, Charles L, Yunis, Carla

“…In six trials comparing the anti–PCSK9 antibody bococizumab with placebo, the reduction in LDL cholesterol at 12 weeks was 55.2 percentage points lower with…”
Get full text

Thyroid Hormone Therapy for Older Adults with Subclinical Hypothyroidism by Stott, David J, Rodondi, Nicolas, Kearney, Patricia M, Ford, Ian, Westendorp, Rudi G.J, Mooijaart, Simon P, Sattar, Naveed, Aubert, Carole E, Aujesky, Drahomir, Bauer, Douglas C, Baumgartner, Christine, Blum, Manuel R, Browne, John P, Byrne, Stephen, Collet, Tinh-Hai, Dekkers, Olaf M, den Elzen, Wendy P.J, Du Puy, Robert S, Ellis, Graham, Feller, Martin, Floriani, Carmen, Hendry, Kirsty, Hurley, Caroline, Jukema, J. Wouter, Kean, Sharon, Kelly, Maria, Krebs, Danielle, Langhorne, Peter, McCarthy, Gemma, McCarthy, Vera, McConnachie, Alex, McDade, Mairi, Messow, Martina, O’Flynn, Annemarie, O’Riordan, David, Poortvliet, Rosalinde K.E, Quinn, Terence J, Russell, Audrey, Sinnott, Carol, Smit, Jan W.A, Van Dorland, H. Anette, Walsh, Kieran A, Walsh, Elaine K, Watt, Torquil, Wilson, Robbie, Gussekloo, Jacobijn

“…A double-blind, randomized, placebo-controlled, parallel-group trial aimed to determine whether levothyroxine provided clinical benefits in older persons with…”
Get full text

Heart rate variability and first cardiovascular event in populations without known cardiovascular disease: meta-analysis and dose-response meta-regression by Hillebrand, Stefanie, Gast, Karin B, de Mutsert, Renée, Swenne, Cees A, Jukema, J Wouter, Middeldorp, Saskia, Rosendaal, Frits R, Dekkers, Olaf M

“…Heart rate variability (HRV) is associated with cardiovascular disease (CVD) in individuals with known CVD. It is less clear whether HRV is associated with a…”
Get full text

Body fat distribution, in particular visceral fat, is associated with cardiometabolic risk factors in obese women by Elffers, Theodora W, de Mutsert, Renée, Lamb, Hildo J, de Roos, Albert, Willems van Dijk, Ko, Rosendaal, Frits R, Jukema, J Wouter, Trompet, Stella

“…Body fat distribution is, next to overall obesity, an important risk factor for cardiometabolic outcomes in the general population. In particular, visceral…”
Get full text

Alirocumab, evinacumab, and atorvastatin triple therapy regresses plaque lesions and improves lesion composition in mice[S] by Pouwer, Marianne G., Pieterman, Elsbet J., Worms, Nicole, Keijzer, Nanda, Jukema, J. Wouter, Gromada, Jesper, Gusarova, Viktoria, Princen, Hans M.G.

“…Atherosclerosis-related CVD causes nearly 20 million deaths annually. Most patients are treated after plaques develop, so therapies must regress existing…”
Get full text

Meta-analysis of up to 622,409 individuals identifies 40 novel smoking behaviour associated genetic loci by Liu, Mengzhen, Jackson, Victoria E., Melbourne, Carl A., Young, Robin, Batini, Chiara, Afaq, Saima, Agrawal, Arpana, Antoniou, Antonis C., Baumbach, Clemens, Boehnke, Michael, Brazel, David M, Chen, Chu, Corley, Janie, Chou, Yi-Ling, David, Sean P., de Boer, Rudolf A., Dennis, Joe G., Easton, Douglas F., Eaton, Charles, Goate, Alison, Grabe, Hans J., Haessler, Jeff, Hallmans, Göran, Harris, Sarah E., Hattersley, Andrew, Heath, Andrew, Kapoor, Manav, Karpe, Fredrik, Kooner, Jaspal S., Kooperberg, Charles, Laakso, Markku, Langenberg, Claudia, Luan, Jian’an, Madden, Pamela A. F., Mangino, Massimo, Marouli, Eirini, Marten, Jonathan, McGue, Matt, Moayyeri, Alireza, Moitry, Marie, Naheed, Aliya, Nauck, Matthias, Neville, Matthew J., Nielsen, Sune Fallgaard, Perola, Markus, Pharoah, Paul D. P., Rasheed, Asif, Renström, Frida, Rice, John, Rohde, Rebecca, Samuel, Maria, Scholte, Steven H, Scott, Robert A., Shao, Yaming, Smith, Jennifer A., Starr, John M., Stram, Danielle, Stringham, Heather M., Tachmazidou, Ioanna, Tardif, Jean-Claude, Thompson, Deborah J., Tindle, Hilary A., Tragante, Vinicius, Trompet, Stella, Turcot, Valerie, Tyrrell, Jessica, van der Leij, Andries R, van der Meer, Peter, Verweij, Niek, Warren, Helen R., Weiss, Stefan, Wetherill, Leah, Yaghootkar, Hanieh, Jiang, Yu, Chen, Fang, Zhan, Xiaowei, Zhang, Weihua, Zhao, Wei, Zhao, Wei, Zhou, Kaixin, Amouyel, Philippe, Blankenberg, Stefan, Caulfield, Mark J., Chowdhury, Rajiv, Cucca, Francesco, Deary, Ian J., Deloukas, Panos, Ferrario, Marco, Frossard, Philippe, Hall, Ian P., Jansson, Jan-Håkan, Kee, Frank, Munroe, Patricia B., Palmer, Colin N. A., Sattar, Naveed, Spector, Timothy, Zeggini, Eleftheria, Saleheen, Danish, Danesh, John, Tobin, Martin D.

“…Smoking is a major heritable and modifiable risk factor for many diseases, including cancer, common respiratory disorders and cardiovascular diseases. Fourteen…”
Get full text

Genetically determined NLRP3 inflammasome activation associates with systemic inflammation and cardiovascular mortality by Schunk, Stefan J, Kleber, Marcus E, März, Winfried, Pang, Shichao, Zewinger, Stephen, Triem, Sarah, Ege, Philipp, Reichert, Matthias C, Krawczyk, Marcin, Weber, Susanne N, Jaumann, Isabella, Schmit, David, Sarakpi, Tamim, Wagenpfeil, Stefan, Kramann, Rafael, Boerwinkle, Eric, Ballantyne, Christie M, Grove, Megan L, Tragante, Vinicius, Pilbrow, Anna P, Richards, A Mark, Cameron, Vicky A, Doughty, Robert N, Dubé, Marie-Pierre, Tardif, Jean-Claude, Feroz-Zada, Yassamin, Sun, Maxine, Liu, Chang, Ko, Yi-An, Quyyumi, Arshed A, Hartiala, Jaana A, Tang, W H Wilson, Hazen, Stanley L, Allayee, Hooman, McDonough, Caitrin W, Gong, Yan, Cooper-DeHoff, Rhonda M, Johnson, Julie A, Scholz, Markus, Teren, Andrej, Burkhardt, Ralph, Martinsson, Andreas, Smith, J Gustav, Wallentin, Lars, James, Stefan K, Eriksson, Niclas, White, Harvey, Held, Claes, Waterworth, Dawn, Trompet, Stella, Jukema, J Wouter, Ford, Ian, Stott, David J, Sattar, Naveed, Cresci, Sharon, Spertus, John A, Campbell, Hannah, Tierling, Sascha, Walter, Jörn, Ampofo, Emmanuel, Niemeyer, Barbara A, Lipp, Peter, Schunkert, Heribert, Böhm, Michael, Koenig, Wolfgang, Fliser, Danilo, Laufs, Ulrich, Speer, Thimoteus

“…Abstract Aims Inflammation plays an important role in cardiovascular disease (CVD) development. The NOD-like receptor protein-3 (NLRP3) inflammasome…”
Get full text

Prophylactic Use of Implantable Cardioverter-Defibrillators in the Prevention of Sudden Cardiac Death in Dialysis Patients: The Prospective, Randomized, Controlled ICD2 Trial by Jukema, J Wouter, Timal, Rohit J, Rotmans, Joris I, Hensen, Liselotte C R, Buiten, Maurits S, de Bie, Mihaly K, Putter, Hein, Zwinderman, Aeilko H, van Erven, Lieselot, Krol-van Straaten, M Jacqueline, Hommes, Nienke, Gabreëls, Bas, van Dorp, Wim, van Dam, Bastiaan, Herzog, Charles A, Schalij, Martin J, Rabelink, Ton J

“…BACKGROUND:Patients with end-stage renal disease who are undergoing dialysis are reported to be at high risk of sudden cardiac death (SCD), and to date, no…”
Get full text

Effect of alirocumab on cardiovascular outcomes after acute coronary syndromes according to age: an ODYSSEY OUTCOMES trial analysis by Sinnaeve, Peter R, Schwartz, Gregory G, Wojdyla, Daniel M, Alings, Marco, Bhatt, Deepak L, Bittner, Vera A, Chiang, Chern-En, Correa Flores, Roger M, Diaz, Rafael, Dorobantu, Maria, Goodman, Shaun G, Jukema, J Wouter, Kim, Yong-Un, Pordy, Robert, Roe, Matthew T, Sy, Rody G, Szarek, Michael, White, Harvey D, Zeiher, Andreas M, Steg, Ph Gabriel

“…Abstract Aims Lowering low-density lipoprotein cholesterol (LDL-C) reduces cardiovascular risk irrespective of age, but the evidence is less strong for older…”
Get full text

T cell co-stimulation and co-inhibition in cardiovascular disease: a double-edged sword by Simons, Karin H., de Jong, Alwin, Jukema, J. Wouter, de Vries, Margreet R., Arens, Ramon, Quax, Paul H. A.

“…The role of inflammation in cardiovascular disease (CVD) is now widely accepted. Immune cells, including T cells, are influenced by inflammatory signals and…”
Get full text

Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: Rationale and design of the ODYSSEY Outcomes trial by Schwartz, Gregory G., MD, PhD, Bessac, Laurence, MD, Berdan, Lisa G., PA, MHS, Bhatt, Deepak L., MD, MPH, Bittner, Vera, MD, Diaz, Rafael, MD, Goodman, Shaun G., MD, MSc, Hanotin, Corinne, MD, Harrington, Robert A., MD, Jukema, J. Wouter, MD, PhD, Mahaffey, Kenneth W., MD, Moryusef, Angèle, MD, Pordy, Robert, MD, Roe, Matthew T., MD, MPH, Rorick, Tyrus, RN, Sasiela, William J., PhD, Shirodaria, Cheerag, MBBS, Szarek, Michael, PhD, Tamby, Jean-François, MD, Tricoci, Pierluigi, MD, White, Harvey, MBBS, DSc, Zeiher, Andreas, MD, Steg, Philippe Gabriel, MD

“…Background Following acute coronary syndrome (ACS), the risk for future cardiovascular events is high and is related to levels of low-density lipoprotein…”
Get full text

Prognostic Value of Multislice Computed Tomography Coronary Angiography in Patients With Known or Suspected Coronary Artery Disease by Pundziute, Gabija, MD, Schuijf, Joanne D., MSc, Jukema, J. Wouter, MD, PhD, Boersma, Eric, PhD, de Roos, Albert, MD, PhD, van der Wall, Ernst E., MD, PhD, Bax, Jeroen J., MD, PhD

“…Prognostic Value of Multislice Computed Tomography Coronary Angiography in Patients With Known or Suspected Coronary Artery Disease Gabija Pundziute, Joanne D…”
Get full text

Thrombin-Receptor Antagonist Vorapaxar in Acute Coronary Syndromes by Tricoci, Pierluigi, Huang, Zhen, Held, Claes, Moliterno, David J, Armstrong, Paul W, Van de Werf, Frans, White, Harvey D, Aylward, Philip E, Wallentin, Lars, Chen, Edmond, Lokhnygina, Yuliya, Pei, Jinglan, Leonardi, Sergio, Rorick, Tyrus L, Kilian, Ann M, Jennings, Lisa H.K, Ambrosio, Giuseppe, Bode, Christoph, Cequier, Angel, Cornel, Jan H, Diaz, Rafael, Erkan, Aycan, Huber, Kurt, Hudson, Michael P, Jiang, Lixin, Jukema, J. Wouter, Lewis, Basil S, Lincoff, A. Michael, Montalescot, Gilles, Nicolau, José Carlos, Ogawa, Hisao, Pfisterer, Matthias, Prieto, Juan Carlos, Ruzyllo, Witold, Sinnaeve, Peter R, Storey, Robert F, Valgimigli, Marco, Whellan, David J, Widimsky, Petr, Strony, John, Harrington, Robert A, Mahaffey, Kenneth W

“…In this trial, vorapaxar, a protease-activated–receptor 1 antagonist that inhibits thrombin-induced platelet activation, was not effective in reducing the…”
Get full text